

AD-A225 556

4

IMMUNE RESPONSE TO CRYPTOSPORIDIOSIS IN PHILIPPINE CHILDREN


M.A. Laxer, A.K. Alcantara, M. Javato-Laxer, D.M. Menorca,  
M.T. Fernando, and C.P. Ranoa

DTIC FILE COPY

REPORT NO.

TR-1079

DTIC  
ELECTE  
AUG 23 1990  
S D D  
to



DISTRIBUTION STATEMENT A  
Approved for public release;  
Distribution Unlimited

**UNITED STATES NAVAL  
MEDICAL RESEARCH UNIT NO. TWO**

APO SAN FRANCISCO, CALIFORNIA 96528 - 5000

NAVAL MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
BETHESDA, MARYLAND

90 08 22 ' 088

### ADMINISTRATIVE INFORMATION

C.G. HAYES, Ph.D.  
Chief Scientist

This work was supported by funds provided by the Naval Medical Research and Development Command for Work Unit 3M162770A870.AQ220.

Distribution of this document is unlimited.

J.C. COOLBAUGH  
CAPT MSC USN  
Commanding Officer

By \_\_\_\_\_  
 Date: 10/1/01

A-1 20



## IMMUNE RESPONSE TO CRYPTOSPORIDIOSIS IN PHILIPPINE CHILDREN

MARC A. LAXER, ALBERTO K. ALCANTARA, MARIVYL JAVATO-LAXER,  
DANILO M. MENORCA, MARCELINO T. FERNANDO, AND CATHERINE P. RANOA  
*U.S. Naval Medical Research Unit No. 2, APO San Francisco, California; and San Lazaro  
Hospital, Manila, Philippines*

**Abstract.** An ELISA was used to measure the *Cryptosporidium*-specific IgA, IgG, and IgM antibody levels in serum, stool, and duodenal fluid of 15 Filipino children. Antibody levels were measured on admission to the hospital, 1 week later, and at a 6 week follow-up examination. Delayed type hypersensitivity skin tests were used to assay cell mediated immunity (CMI), iron status was measured by serum iron tests and total iron binding capacity, and the degree of malnutrition was determined by clinical examination. Antibody response to *Cryptosporidium* was qualitatively and quantitatively strong and maintained over time. All subjects showed impaired CMI early with some reconstitution after 6 weeks. All subjects showed some degree of malnutrition and/or depleted iron status.

*Cryptosporidium* ssp. is generally accepted as a pathogen of the digestive tract in humans and in animals.<sup>1</sup> Although there is a considerable body of literature covering the biology and epidemiology of *Cryptosporidium*,<sup>1-8</sup> there is little known about the immunity to cryptosporidial infection in humans. In other coccidian infections, it is believed that either cell-mediated immune response (CMI) or an antibody-dependent cell mediated cytotoxic effect (ADCC) is the primary defense.<sup>9,10</sup> Recent investigations on immunity to *Cryptosporidium* advance similar findings.<sup>11,12</sup> We investigated the immune response to *Cryptosporidium* in infants and young children with diarrhea admitted to San Lazaro Hospital (SLH), a large infectious disease hospital, in Manila. We were interested in the antibody response over time, the cell mediated immune response, and the correlation between the level of immunity and the state of nutrition, particularly iron status. The study period was July 1986–October 1987, and we were able to update the existing literature on the epidemiology of cryptosporidiosis in the Philippines.<sup>2</sup>

### MATERIALS AND METHODS

#### *Subjects*

Children 1–24 months of age with diarrhea who were admitted to SLH were screened by stool examination for *Cryptosporidium*. Those found positive by modified Kinyoun stain were

considered for enrollment in the study. Although there were several cases of infection with multiple enteric pathogens, the subjects selected for enrollment were infected only with *Cryptosporidium* ssp. Upon obtaining informed consent from the parents or legal guardians, the children were formally enrolled. Fifty-six age- and sex-matched controls were selected from patients admitted to the hospital for any condition other than gastrointestinal disease.

#### *Specimens*

Immediately following enrollment, a stool sample, 3–5 ml venous blood, and a duodenal fluid sample were obtained. Stool and blood were collected in the usual manner, and duodenal fluid was collected by either naso-gastric intubation or string capsule (Entero-Test®, HDC Corp., Mountain View, CA). Stool specimens were analyzed by Rotazyme ELISA kits (Abbott Labs, North Chicago, IL) for rotavirus and plated on appropriate enteric media; colonies were identified by the API System (API Systems, SA, La Balme les Grottes, France). Specimens were labeled and frozen at –60°C for future use. This procedure was repeated 1 week and 6 weeks post-enrollment for each subject that could be located.

#### *ELISA*

To determine the levels of *Cryptosporidium*-specific IgA, IgG, and IgM antibodies in the stool,

TABLE I

*Enteric pathogens identified from pediatric diarrhea cases admitted to San Lazaro Hospital, Manila, July 1986–October 1987*

| Organism isolated                          | Total number positive | Percent positive |
|--------------------------------------------|-----------------------|------------------|
| 1. Rotavirus                               | 487                   | 59.2             |
| 2. <i>Ascaris lumbricoides</i>             | 110                   | 31.4             |
| 3. <i>Trichuris trichiura</i>              | 76                    | 9.2              |
| 4. <i>Salmonella</i> group B               | 71                    | 8.6              |
| 5. <i>Cryptosporidium</i> ssp.             | 70                    | 8.5              |
| 6. <i>Vibrio cholera</i>                   | 55                    | 6.7              |
| 7. <i>Shigella flexneri</i> (B)            | 39                    | 4.7              |
| 8. <i>Salmonella</i> group E               | 26                    | 3.2              |
| 9. <i>Aeromonas hydrophila</i>             | 22                    | 2.7              |
| 10. <i>Blastocystis hominis</i>            | 9                     | 1.1              |
| 11. <i>Campylobacter jejuni</i>            | 7                     | 0.85             |
| 12. <i>Entamoeba coli</i>                  | 6                     | 0.72             |
| 13. Hookworm                               | 6                     | 0.72             |
| 14. <i>Salmonella</i> group C <sub>2</sub> | 3                     | 0.4              |
| 15. <i>Vibrio thuyalis</i>                 | 3                     | 0.4              |
| 16. <i>Giardia lamblia</i>                 | 3                     | 0.4              |
| 17. <i>Salmonella</i> group C <sub>1</sub> | 2                     | 0.24             |
| 18. <i>Shigella sonnei</i> (D)             | 1                     | 0.12             |
| 19. <i>Enterobius vermicularis</i>         | 1                     | 0.12             |

Total number of patients = 823.

serum, and duodenal fluid samples, an enzyme-linked immunosorbent assay (ELISA) was performed. The method was modified from that of Ungar and others.<sup>13</sup> *Cryptosporidium parvum* oocysts used as solid phase antigen were supplied by Bruce Anderson, University of Idaho, Caldwell, ID and Ron Fayer, USDA, Beltsville, MD. Oocysts in bovine fecal material were cleaned and concentrated by discontinuous density gradient centrifugation in Percoll as previously described.<sup>14</sup> After concentration, 250–300 k oocysts suspended in coating buffer were placed in each well of 96-well Immulon-2 \* flat-bottomed plates (Dynatech Laboratories, Chantilly, VA). Plates were allowed to coat overnight at 4°C. Plates were then blocked by the addition of 5% horse serum in phosphate buffered saline (PBS) and stored at –60°C until ready for use. Prior to assay, plates were washed 2 times in washing buffer. Samples to be assayed (serum, stool, and duodenal fluid) were first processed to separate the IgG fractions from the IgA and IgM fractions. This was done using the Quik-Sep System II \* column chromatography kit (Isolab Inc., Akron, OH). After separation, samples were diluted as follows: all serum antibodies, 1:100; stool and duodenal fluid IgG, 1:26; and stool and duodenal fluid IgA and IgM, 1:10. These samples, in 50  $\mu$ l

portions, were then added to appropriate wells, incubated for 1 hr at 37°C, then washed 3 times in buffer. Conjugates of anti-human IgA, IgG, and IgM with horseradish peroxidase (Sigma, St. Louis, MO) in 50  $\mu$ l portions of 1:1,000 dilution were then added to the wells, incubated for 1 hr at 37°C, and washed as before. Substrate OPD (Abbot Laboratories, North Chicago, IL) was then added to the wells, allowed to react for 30 min, and then stopped with H<sub>2</sub>SO<sub>4</sub>; the absorbance was read at 402 nm on a Titertek \* Multiscan plate reader (Titertek, Flow Labs, Inglewood, CA). Known positive and negative control samples plus PBS were run. To establish cutoff values, serum samples were obtained from 12 healthy infants at a U.S. Air Force Hospital in the Philippines. Normal control sera from SLH were not used because of high reactivity to *C. parvum* oocysts, suggesting prior exposure to the organism. Multiple portions of each of the samples from the 12 healthy infants were assayed for IgA, IgG, and IgM by our ELISA procedure.

#### *Indirect immunofluorescent antibody assay*

Samples of stool, serum, and duodenal fluid were screened by indirect immunofluorescent antibody assay (IFA) using methods previously described.<sup>15</sup> Briefly, *C. parvum* oocysts were air-dried and methanol fixed on glass slides. Samples, after Quik Sep treatment, were added to the smear and incubated. Serum samples were diluted 1:100, stool and duodenal fluid IgG samples were diluted 1:26, and stool and duodenal fluid IgA and IgM samples were diluted 1:10. Slides were washed thoroughly, and a 1:5 dilution of goat anti-human IgA, IgG, and IgM conjugated to FITC (Sigma) were added and incubated for 30–60 min at 37°C. Slides were washed again, mounted, and observed on a fluorescence microscope.

#### *Total antibody*

Total antibody levels for IgA, IgG, and IgM, expressed in mg/dL, were obtained for each sample by the radial immunodiffusion (RID) method. RID assays for the 3 subclasses of human antibodies were performed using the Accra Assay \* series (ICN Biomedicals, Costa Mesa, CA) and were computed using the end point method as described in the product insert.




FIGURE 1. The number of cases of cryptosporidiosis was greatest in children 7-18 months of age. There was no detectable difference in sex distribution.

#### Cell mediated immunity

The subjects' ability to mount a cell mediated response (CMI) was evaluated using a delayed type hypersensitivity (DTH) test administered to the forearm or thigh. The resulting indurations were measured after 48 hr and a score derived. In order to standardize the procedure, the Multitest CMI kit (Merieux Institute, Miami, FL) was used. The 7 pre-measured antigens provided in the kit cover a broad range of substances that should give a reasonably accurate assessment of CMI status.

#### Serum iron and total iron binding capacity

Acute, 1 week, and 6 week serum samples from each subject were analyzed to obtain serum iron and total iron binding capacity (TIBC) using the Gemini serum iron/TIBC reagent kit and the Gemini Miniature Centrifugal Analyzer (Electro Nucleonics, Fairfield, NJ).

### RESULTS

#### Epidemiological data

Our study in July 1986–October 1987 showed a prevalence of 8.5% for *Cryptosporidium* among 823 subjects sampled making it the fifth most common isolate (Table 1). Because SLH is a large charity hospital, the patients represent the lowest income class in the metropolitan area. These patients often live with poor hygiene and sanitation, resulting in maximum exposure to enteropathogens early in life. The largest number of




FIGURE 2. In support of previous studies, we detected a slight seasonality for cryptosporidiosis, with more cases occurring during the warmer, rainy months.

cases were in the 7-18 month age group with almost equal sex distribution (Fig. 1). To evaluate the possibility that some of the isolates could reflect asymptomatic carriage of *Cryptosporidium*, we sampled 74 non-diarrheic individuals including some immediate family members of the enrolled subjects. No oocysts were found. We found a slight indication of seasonality in the occurrence of cases (Fig. 2), with the higher numbers appearing during the rainy months.

#### Humoral immunity

**ELISA.** Among the 70 diagnosed cases of cryptosporidiosis, 21 subjects completed the entire course of specimen collection. Samples of serum, stool, and duodenal fluid from acute, 1 week, and 6 week collection times of all completed subjects were analyzed by ELISA for levels of *Cryptosporidium* oocyst-specific IgA, IgG, and IgM antibodies (Table 2). The serum samples showed mean optical density (OD) values significantly higher than controls for all 3 subclasses at the 3 different collection times, although there was no significant difference between the acute, 1 week, and 6 week levels. The duodenal fluid samples only showed higher mean OD values for IgA at the 6 week collection. Stool samples showed significantly higher mean OD values for IgM at all 3 collections and for IgG at the acute collection; however, the values decreased over time. We were able to locate 6 subjects at 6 months post-study and collected serum and stool samples. We found an elevated antibody response to *Cryptosporidium* among these samples (Table 3).

TABLE 2  
Cryptosporidium specific IgA, IgG, and IgM antibody levels in serum, duodenal fluid, and stool as determined by ELISA\*

|                |     | Examination    |                |                | Normal control† |
|----------------|-----|----------------|----------------|----------------|-----------------|
|                |     | Acute          | 1 week         | 6 weeks        |                 |
| Serum          | IgA | 0.18 (0.177)‡  | 0.18 (0.183)‡  | 0.172 (0.125)‡ | 0.012 (0.005)   |
|                | IgG | 0.396 (0.260)‡ | 0.46 (0.248)‡  | 0.515 (0.229)‡ | 0.283 (0.096)   |
|                | IgM | 0.445 (0.159)‡ | 0.461 (0.033)‡ | 0.484 (0.137)‡ | 0.136 (0.015)   |
| Duodenal fluid | IgA | 0.101 (0.132)  | 0.16 (0.182)   | 0.231 (0.193)§ | 0.05 (0.021)    |
|                | IgG | 0.077 (0.066)  | 0.048 (0.046)  | 0.089 (0.116)  | 0.037 (0.025)   |
|                | IgM | 0.23 (0.101)   | 0.258 (0.132)  | 0.288 (0.134)  | 0.285 (0.036)   |
| Stool          | IgA | 0.293 (0.368)  | 0.254 (0.268)  | 0.222 (0.2)    | 0.154 (0.019)   |
|                | IgG | 0.07 (0.068)§  | 0.04 (0.031)   | 0.037 (0.028)  | 0.027 (0.012)   |
|                | IgM | 0.32 (0.183)¶  | 0.27 (0.119)‡  | 0.254 (0.098)‡ | 0.153 (0.019)   |

\* Mean (SD) of optical density values read at 402 nm absorbance.

† Controls for serum were a pool of 12 healthy infants from Clark Air Force Base, Philippines. Controls for stool and duodenal fluid were from healthy infants from SLH.

‡ Statistically significant difference between sample mean and normal control mean,  $P < 0.001$ , Student's  $t$ -test (2-tailed).

§ Statistically significant difference between sample mean and normal control mean,  $P = 0.01$ , Student's  $t$ -test (2-tailed).

¶ Statistically significant difference between sample mean and normal control mean,  $P = 0.001$ , Student's  $t$ -test (2-tailed).

IFA. To visualize the antigen-antibody reactions and to help support the ELISA results, an IFA was run. The results of the IFA appear in Figure 3. Clear evidence of antibody binding can be seen on both the oocyst walls and, in some cases, on the sporozoites within.

Total antibody. Total antibody levels in serum, stool, and duodenal fluid were assayed by RID. Only the IgA subclass showed a significant decrease from normal controls, and this appeared at all 3 collection times in serum and duodenal fluid (Table 4).

CMI. Delayed-type hypersensitivity skin reaction was used as an indicator of subjects' CMI response. The test was performed on 7 of the 21 subjects at enrollment and at the 6 week follow-up (Table 5). Age matched controls were tested once. On initial testing, all subjects showed total skin anergy compared to controls who reacted to a variety of antigens. At the 6 week follow-up, the mean score for the experimental group was still significantly lower than the controls, although there was an increase in DTH response from the initial test.

Iron status. Serum samples drawn at the acute, 1 week, and 6 week collection times were analyzed for serum iron, TIBC, and percent saturation of transferrin. Serum iron levels at all 3 collection times were significantly lower than control values, although there was no significant fluctuation of values between collection times (Fig. 4). Over the 6 week time span, TIBC increased to the point where the 6 week values were significantly higher than control values. Corre-

spondingly, the percent saturation of transferrin decreased from 18.3% to 13.1% over the 6 week period. The normal control value for percent saturation was 39.4% (Fig. 5). Subjective and objective evaluations of these patients by our clinical team indicated the existence of some degree of malnutrition in every case.

## DISCUSSION

The immune responses to coccidial infections have been characterized as primary CMI with strong T cell dependency,<sup>9,16</sup> as antibody mediated (citing the enhancement of primary in-

TABLE 3  
Six month follow-up assay for Cryptosporidium antibodies from 6 return subjects\*

|       |           | IgA               | IgG               | IgM               |
|-------|-----------|-------------------|-------------------|-------------------|
| Serum | Subjects  | 0.35†<br>(0.227)  | 0.335†<br>(0.126) | 0.433†<br>(0.136) |
|       | Controls‡ | 0.261<br>(0.024)  | 0.239<br>(0.027)  | 0.281<br>(0.124)  |
| Stool | Subjects  | 0.095†<br>(0.065) | 0.044†<br>(0.01)  | 0.101†<br>(0.062) |
|       | Controls§ | 0.491<br>(1.152)  | 0.05<br>(0.011)   | 0.055<br>(0.023)  |

\* ELISA results reported as mean optical density read at 402 nm. Mean (standard deviation) of 3 readings of a single test of each pooled sample from the 6 subjects.

† Statistically significant difference between sample mean and normal control mean,  $P < 0.001$ , Student's  $t$ -test.

‡ Normal controls were 12 healthy infants from Clark Air Force Base, Philippines.

§ Normal controls were 6 healthy children from San Lazaro Hospital/NAMRU-2 staff.




FIGURE 3. Results of IFA using *Cryptosporidium parvum* oocysts and subject sera and stool antibodies. A. Serum IgA shows strong reaction to oocysts. B. Stool IgG shows strong reaction to oocysts. C. Stool IgA shows distinct reaction to oocysts and sporozoites. Bars = 10  $\mu$ m.

fection in antibody deficient mice), or as an interplay of humoral and CMI with ADCC as a strong possibility.<sup>10</sup> The immune response to *Cryptosporidium* has similarly been described as either CMI, as evidenced by the course of the disease in AIDS patients, or humoral,<sup>12,17</sup> with reference to the increased susceptibility of hypogammaglobulinemic patients.<sup>11</sup>

Our longitudinal study of 21 children with cryptosporidiosis shows a marked cryptosporidial antibody response for IgA, IgG, and IgM in serum. This response was maintained over time, as seen in 6 subjects in a 6 month follow-up screening (Table 3). These findings were consistent with previously reported work,<sup>1,17</sup> and probably indicate continued exposure to the organism with resulting boosting effect. The total serum antibody response for IgG and IgM was com-

parable to controls, although there was a lower value of total serum IgA in the subjects.

In stool samples, IgM was found in significant amounts over a period of 6 weeks, although the values decreased over time. IgA and IgG were found in detectable levels, though there was no difference from controls. The decreased antibody levels in stools may have resulted from the flushing action of prolonged, severe diarrhea, rather than from decreased production or secretion.<sup>18</sup>

In duodenal fluid samples, only IgA was found at significant levels and only at the 6 week sampling time. We do not believe that the results for duodenal IgG and IgM antibody levels reflect a true picture of the situation. Due to delays in processing, a considerable amount of IgG and IgM may have been degraded by enzymatic activity present in the fluid prior to freezing, stor-

TABLE 4

Total antibody concentration (mg/dL) over time, in serum, stool and duodenal fluid, as determined by radial immunodiffusion assay (RID)

|                |     | Acute | 1 week | 6 weeks | Normal controls | Normal range† |
|----------------|-----|-------|--------|---------|-----------------|---------------|
| Serum          | IgA | 97    | 87     | 102     | 280*            | 19-119        |
|                | IgG | 1,383 | 1,343  | 1,375   | 2,042           | 258-1,393     |
|                | IgM | 282   | 275    | 253     | 150             | 14-114        |
| Duodenal fluid | IgA | 1     | 1      | 2       | 582†            | §             |
|                | IgG | 5     | 5      | 8       | 1               | §             |
|                | IgM | 1     | 1      | 0       | 1               | §             |
| Stool          | IgA | 11    | 14     | 11      | 2               | §             |
|                | IgG | 5     | 11     | 3       | 1               | §             |
|                | IgM | 2     | 7      | 4       | 1               | §             |

\* Statistically significant difference between 3 sample means and control mean,  $P = 0.02$ , 1-way ANOVA.

† Statistically significant difference between 3 sample means and control mean,  $P < 0.001$ , 1-way ANOVA.

‡ Normal ranges for children up to 24 months old.

§ Normal values not reported.

TABLE 5

Cell mediated immune response as determined by delayed type hypersensitivity reaction using the Multitest<sup>®</sup> CMI kit

|                          | Mean scores* |          |
|--------------------------|--------------|----------|
|                          | Subjects     | Controls |
| Initial test             | 0/0†         | 4/15     |
| Follow up test (6 weeks) | 3/6‡         | ND       |

\* Composite score is the total number of antigens showing positive reaction sum of diameters in mm of measured induration. Antigens used were tetanus, diphtheria, Streptococcus, tuberculosis, glycerin control, Candida, Trichophyton, Proteus.

† Statistically significant difference between sample mean and control mean  $P < 0.001$ , Student's  $t$ -test (2-tailed).

‡ Statistically significant difference between sample mean and control mean  $P = 0.03$ , Student's  $t$ -test (2-tailed).

age, and assay. Previous work has shown considerable IgG and IgM secretion into the duodenum.<sup>19,20</sup> We feel that a similar situation existed in our study, although it may have been masked by problems in technique.

The antibody response to *Cryptosporidium* in our subjects was remarkable qualitatively as well as quantitatively. The 3 subclasses showed distinct affinity for the oocyst wall and the pellicle, or outer membrane, of the sporozoites. As with other coccidia, surface structures on *Cryptosporidium* are probably involved in infectivity and may be targets of a protective immune response.<sup>21</sup> These structures on the oocyst have been characterized as carbohydrate moieties, either alone or in conjunction with lipids or proteins.<sup>22</sup> Serum IgM showed the strongest binding response to surface structures on both the oocysts and sporozoites as determined by immunoelectron microscopy (data not shown).

We wanted to evaluate the CMI status of our subjects. We initially intended to perform T4/T8 ratios to measure CMI competence. However, the amount of blood required was considered excessive for the age and nutritional state of the children, and so an alternative method was employed. DTH as expressed by skin reaction was the method of choice. The CMI Multitest uses a battery of 7 common antigens and is regarded as an adequate test of CMI in infants and young children.<sup>23</sup> On initial testing, all 7 subjects showed total skin anergy. At 6 weeks follow-up, there was a slight increase in the test scores, but they were still significantly below the normal control values. We were also able to test 6 subjects at a 6 month follow-up; at this time there were some increases in skin reactivity, indicating a partial reconstitution of CMI competence.




FIGURE 4. Subjects showed decreased serum iron levels at 3 different sampling times as compared to controls.

\* $P < 0.001$ , Student's  $t$ -test. Statistically significant difference between sample mean and negative control mean.

The finding of impaired CMI in our subjects was not unexpected.<sup>24-26</sup> These children displayed varying degrees of malnutrition (as determined by Gomez's classification)<sup>27</sup> which, based on their economic status and lifestyle, was probably a pre-existing condition to their cryptosporidiosis. The relationship between nutritional state and immunity is well documented. Malnutrition appears to have little or no effect on the quality or quantity of antibody production, but it does impair CMI.<sup>28</sup>

We were interested in the role of iron and its effect on CMI. Previous studies have shown that iron malnutrition was correlated with CMI impairment, particularly lymphocyte function,




FIGURE 5. Subjects showed increasing total iron binding capacity and decreasing percent saturation of transferrin over time, indicative of iron deficiency anemia, as compared to controls.

\* $P = 0.002$ , Student's  $t$ -test. Statistically significant difference between sample mean and negative control mean.



phagocytosis, and neutrophil bactericidal activity, while antibody responses and complement were normal.<sup>29-31</sup> Our results (Figs. 4, 5) show decreased serum iron, increased TIBC and decreasing percent saturation of transferrin. This is the classical picture of iron deficiency anemia. These results support the existing work on iron status and immunity.

A question that we could not resolve was the role of *Cryptosporidium* in iron malnutrition. In a population suffering from protein calorie malnutrition (PCM), there is probably concomitant iron deficiency and impaired CMI. We speculate that *Cryptosporidium*, by virtue of its preference for parasitizing the brush border of enterocytes, may incapacitate enough absorptive surface and molecular transport mechanisms to further disrupt iron absorption, thus precipitating a vicious circle of nutrient deficit, impaired CMI, increased and prolonged infection, and further nutrient deficit.

In our study of cryptosporidiosis in Philippine children, we found a prevalence rate of 8.5% in a sample population consisting of subjects 1-24 months of age, with no apparent or documented immunodeficiency disorders. There was no significant difference in sex distribution. The greatest number of cases occurred in the 7-18 month age group. The highest number of cases occurred in the warm wet months. Our subjects were almost all from low income families where sanitation and personal hygiene were minimal. Our epidemiological findings are in agreement with previously published studies on children from developing countries,<sup>1-4,6-8,32</sup> except we show an increase in prevalence (2.9% vs. 8.5%) for the Philippines since the initial 1985 study.<sup>2</sup> This may be due to a difference in methodology. In 74 non-diarrheic individuals, we found no asymptomatic carriage of *Cryptosporidium parvum*. This may be a reflection of the small sample size, since other studies have shown evidence of asymptomatic carriage.<sup>33</sup>

In conclusion, we examined a sample population of pediatric subjects diagnosed as having cryptosporidial diarrhea but with no other documented immunodeficiencies. We found a marked and prolonged antibody response to *Cryptosporidium*, but impaired CMI. The infection cleared spontaneously over time and CMI was reconstituted. The prolonged antibody response, and specifically the IgM response, may reflect a situation of continuous exposure to the

organism in a contaminated environment with a subsequent boosting effect. The CMI deficit may have been related to general PCM or, more specifically, to iron deficiency which was found in all subjects. These findings, and the published results of other workers,<sup>34-35</sup> lead us to conclude that the immune response to cryptosporidiosis in our subjects is probably an antibody dependent cell-mediated cytotoxic effect of unknown mechanism. For clinicians in developing countries who are faced with pediatric cases of cryptosporidiosis we recommend, in addition to routine supportive care, the monitoring of CMI status by skin testing and an aggressive program of nutritional therapy aimed at reconstituting the cell mediated immune response. Although iron may be an important factor in rebuilding ADCC immunity, intensive iron supplementation should be approached with caution.<sup>36</sup>

**Acknowledgments:** We would like to thank Peter Echeverria for guidance with the initial project design. We would also like to thank the following individuals for their exemplary technical skills in the areas of microbiology, clinical laboratory methods, and general support: Soledad L. Bautista, Tessie Gavina, Natividad Ramilo, Mene Cui, Renato Leano, Leah Corpuz, Lily Alquiza, Fe Baraceres, and Gloria Nuguid. We would also like to offer special thanks to Rolando Songco and the staff physicians at the Hospital of Infant Jesus, Manila, for participating in the study.

**Authors' addresses:** Marc A. Laxer, Alberto K. Alcantara, Marivyl Javato-Laxer, Danilo M. Menorca, U.S. Naval Medical Research Unit No. 2, APO San Francisco, CA 96528-5000. Marcelino T. Fernando and Catherine P. Ranoa, San Lazaro Hospital, Sta. Cruz, Manila, Philippines. Marc A. Laxer, Armed Forces Institute of Pathology, Geographic Pathology, Washington, DC 20306-6000 (present address). Marivyl Javato-Laxer, Department of Infectious Diseases, George Washington University, Washington, DC (present address).

**Financial support:** Naval Medical Research and Development Command, Navy Department, Work Unit 3M16270A870.AQ220.

**Reprint requests:** Publications Office, U.S. Naval Medical Research Unit No. 2, APO San Francisco, CA 96528-5000.

#### REFERENCES

1. Fayer R, Ungar BL. 1986. *Cryptosporidium* spp. and cryptosporidiosis. *Microbiol Rev* 50: 458-483. UI:87089464
2. Cross JH, Alcantara A, Alquiza L, Zaraspe G, Ranoa C. 1985. Cryptosporidiosis in Philippine

- children. *Southeast Asian J Trop Med Public Health* 16: 257-260. UI:86070472
3. Bogaerts J, Lepage P, Rouvroy D, Vandepitte J. 1984. Cryptosporidium spp., a frequent cause of diarrhea in Central Africa. *J Clin Microbiol* 20: 874-876. UI:85080414
4. Guderian RH, Sandoval CA, Mackenzie CD. 1986. Cryptosporidiosis in Ecuadorian children with acute diarrhoea. *J Trop Pediatr* 32: 290-292. UI:87112862
5. Hunt DA, Shannon R, Palmer SR, Jephcott AE. 1984. Cryptosporidiosis in an urban community. *Br Med J [Clin Res]* 289: 814-816. UI:85001199
6. Mata L. 1986. Cryptosporidium and other protozoa in diarrheal disease in less developed countries. *Pediatr Infect Dis* 5: UI:86120660
7. Mata L, Bolanos H, Pizarro D, Vives M. 1984. Cryptosporidiosis in children from some highland Costa Rican rural and urban areas. *Am J Trop Med Hyg* 33: 24-29. UI:84125843
8. Shahid NS, Rahman AS, Anderson BC, Mata LJ, Sanyal SC. 1985. Cryptosporidiosis in Bangladesh. *Br Med J [Clin Res]* 290: 114-115. UI:85098491
9. Lillehoj HS. 1987. Effects of immunosuppression on avian coccidiosis: cyclosporin A but not hormonal bursectomy abrogates host protective immunity. *Infect Immun* 55: 1616-1621. UI:87249167
10. Wakelin D, Grencis RK. 1987. Immunological responses to intestinal parasite infection. Miller K, Nicklin S, eds. *Immunology of the gastrointestinal tract*, vol. II. Boca Raton, FL: CRC Press. 321-325. UI:8602850
11. Janoff EN, Reller LB. 1987. Cryptosporidium species, a protean protozoan. *J Clin Microbiol* 25: 967-975. UI:87251327
12. Casemore DP, Sands RL, Curry A. 1985. Cryptosporidium species, a "new" human pathogen. *J Clin Pathol* 38: 1321-1336. UI:86086475
13. Ungar BL, Soave R, Fayer R, Nash TE. 1986. Enzyme immunoassay detection of immunoglobulin M and G antibodies to Cryptosporidium in immunocompetent and immunocompromised persons. *J Infect Dis* 153: 570-578. UI:86141988
14. Waldman E, Tzipori S, Forsyth JR. 1986. Separation of Cryptosporidium species oocysts from feces by using a percoll discontinuous density gradient. *J Clin Microbiol* 23: 199-200. UI:86196574
15. Laxer MA, Healey MC, Youssef NN. 1987. Production of monoclonal antibodies specific for Eimeria tenella microgametocytes. *J Parasitol* 73: 611-616. UI:87253670
16. Speer CA, Reduker DW, Burgess DE, Whitmire WM, Splitter GA. 1985. Lymphokine-induced inhibition of growth of Eimeria bovis and Eimeria papillata (Apicomplexa) in cultured bovine monocytes. *Infect Immun* 50: 566-571. UI:86032297
17. Campbell PN, Current WL. 1983. Demonstration of serum antibodies to Cryptosporidium sp. in normal and immunodeficient humans with confirmed infections. *J Clin Microbiol* 18: 165-169. UI:83291481
18. Haneberg B, Aarskog D. 1975. Human faecal immunoglobulins in healthy infants and children, and in some with diseases affecting the intestinal tract or the immune system. *Clin Exp Immunol* 22: 210-222. UI:76116885
19. Brantzag P, Bakelien K, Bjerke K, Rognum TO, Scott H, Valnes K. 1987. Nature and properties of the human gastrointestinal immune system. Miller K, Nicklin S, eds. *Immunology of the gastrointestinal tract*, vol. I. Boca Raton, FL: CRC Press. 1-86. UI:8602850
20. Girard JP, Kalbermatten A de. 1970. Antibody activity in human duodenal fluid. *Eur J Clin Invest* 1: 188-195. UI:71182057
21. Riggs MW, Perryman LE. 1987. Infectivity and neutralization of Cryptosporidium parvum sporozoites. *Infect Immun* 55: 2081-2087. UI:87306853
22. Luft BJ, Payne D, Woodmansee D, Kim CW. 1987. Characterization of the Cryptosporidium antigens from sporulated oocysts of Cryptosporidium parvum. *Infect Immun* 55: 2436-2441. UI:88006413
23. Kniker WT, Lesourd BM, McBryde JL, Corriel RN. 1985. Cell-mediated immunity assessed by Multitest CM: skin testing in infants and preschool children. *Am J Dis Child* 139: 840-845. UI:85276156
24. Kocoshis SA. 1986. Diagnosis and treatment of cryptosporidiosis in children. *Compr Ther* 12: 56-61. UI:86191132
25. Macfarlane DE, Horner-Bryce J. 1987. Cryptosporidiosis in well-nourished and malnourished children. *Acta Paediatr Scand* 76: 474-477. UI:87266621
26. Sallon S, Spira DT, Schmid I, Harlap S, Baras M, Jentgens H, Kilcher PR, Deckelbaum RJ. 1986. Cryptosporidium and association with prolonged diarrhea and malnutrition in childhood. *Gastroenterology* 90: 1613.
27. Gomez F, Galvan RR, Frenk S, Munoz JC, Chavez R, Vasquez J. 1956. Mortality in second and third degree malnutrition. *J Trop Pediatr* 2: 77.
28. Puri S, Chandra RK. 1985. Nutritional regulation of host resistance and predictive value of immunologic tests in assessment of outcome. *Pediatr Clin North Am* 32: 499-516. UI:85189568
29. Chandra RK. 1983. Nutrition, immunity, and infection: present knowledge and future directions. *Lancet* 1: 688-691. UI:83165894
30. Joynson DH, Walker DM, Jacobs A, Dolby AE. 1972. Defect of cell-mediated immunity in patients with iron-deficiency anaemia. *Lancet* 2: 1058-1059. UI:73035602
31. van Asbeck BS, Verhoef J. 1983. Iron and host defence. *Eur J Clin Microbiol* 2: 6-10. UI:83182385
32. Shahid NS, Rahman AS, Sanyal SC. 1987. Cryptosporidium as a pathogen for diarrhoea in

- Bangladesh. *Trop Geogr Med* 39: 265-270. UI: 88128001
33. Roberts W, Carr MF, Ma J, Ginsberg A, Green PHR, 1987. Prevalence of *Cryptosporidium* in patients undergoing endoscopy: evidence for an asymptomatic carrier state. *Gastroenterology* 92: 1597.
34. Tagliabue A, Boraschi D, Villa L, Keren DF, Lowell GH, Rappuoli R, Nencioni L, 1984. IgA-dependent cell-mediated activity against enteropathogenic bacteria: distribution, specificity, and characterization of the effector cells. *J Immunol* 133: 988-992. UI:84241150
35. Lowell GH, Smith LF, Griffiss JM, Brandt BL, 1980. IgA-dependent, monocyte-mediated, antibacterial activity. *J Exp Med* 152: 452-457. UI:80250878
36. Weinberg ED, 1974. Iron and susceptibility to infectious disease. *Science* 184: 952-956. UI: 74156209

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |       |                                                |                                                                                      | Form Approved<br>OMB No 0704-0188            |                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------|----------------------------|
| 1a REPORT SECURITY CLASSIFICATION<br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |       |                                                | 1b RESTRICTIVE MARKINGS                                                              |                                              |                            |
| 2a SECURITY CLASSIFICATION AUTHORITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |       |                                                | 3 DISTRIBUTION/AVAILABILITY OF REPORT<br>Distribution of this document is unlimited. |                                              |                            |
| 2b DECLASSIFICATION/DOWNGRADING SCHEDULE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |       |                                                |                                                                                      |                                              |                            |
| 4 PERFORMING ORGANIZATION REPORT NUMBER(S)<br>NAMRU-2-TR-1079                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |       |                                                | 5 MONITORING ORGANIZATION REPORT NUMBER(S)                                           |                                              |                            |
| 6a NAME OF PERFORMING ORGANIZATION<br>U.S. Naval Medical Research Unit No. 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |       | 6b OFFICE SYMBOL<br>(If applicable)<br>NAMRU-2 | 7a NAME OF MONITORING ORGANIZATION                                                   |                                              |                            |
| 6c ADDRESS (City, State, and ZIP Code)<br>APO San Francisco, CA 96528-5000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |       |                                                | 7b ADDRESS (City, State, and ZIP Code)                                               |                                              |                            |
| 8a NAME OF FUNDING/SPONSORING ORGANIZATION<br>Naval Medical Research & Development Command                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |       | 8b OFFICE SYMBOL<br>(If applicable)<br>NMRDC   | 9 PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER                                       |                                              |                            |
| 8c ADDRESS (City, State, and ZIP Code)<br>Bethesda, MD 20814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |       |                                                | 10 SOURCE OF FUNDING NUMBERS                                                         |                                              |                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |       |                                                | PROGRAM ELEMENT NO<br>62770A                                                         | PROJECT NO<br>3M162770A870                   | TASK NO<br>AQ              |
| 11 TITLE (Include Security Classification) (U) Immune response to cryptosporidiosis in Philippine children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |       |                                                |                                                                                      |                                              |                            |
| 12 PERSONAL AUTHOR(S) M.A. Laxer, A.K. Alcantara, M. Javato-Laxer, D. Menorca*, M.T. Fernando*, C. P. Ranao*: *Philippine Department of Health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |       |                                                |                                                                                      |                                              |                            |
| 13a TYPE OF REPORT<br>Technical Report                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |       | 13b TIME COVERED<br>FROM Jul'86 to Oct'87      |                                                                                      | 14 DATE OF REPORT (Year, Month, Day)<br>1990 |                            |
| 15 PAGE COUNT<br>9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |       |                                                |                                                                                      |                                              |                            |
| 16 SUPPLEMENTARY NOTATION Published in the American Journal of Tropical Medicine and Hygiene, 42(2):131-139, 1990                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |       |                                                |                                                                                      |                                              |                            |
| 17 COSATI CODES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |       |                                                | 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number)     |                                              |                            |
| FIELD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | GROUP | * SUB-GROUP                                    | Cryptosporidiosis Philippine children                                                |                                              |                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |       |                                                |                                                                                      |                                              |                            |
| 19 ABSTRACT (Continue on reverse if necessary and identify by block number)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |       |                                                |                                                                                      |                                              |                            |
| <p>An ELISA was used to measure the <i>Cryptosporidium</i>-specific IgA, IgG, and IgM antibody levels in serum, stool, and duodenal fluid of 15 Filipino children. Antibody levels were measured on admission to the hospital, 1 week later, and at a 6-week follow-up examination. Delayed type hypersensitivity skin tests were used to assay cell mediated immunity (CMI), iron status was measured by serum iron tests and total iron binding capacity, and the degree of malnutrition was determined by clinical examination. Antibody response to <i>Cryptosporidium</i> was qualitatively and quantitatively strong and maintained over time. All subjects showed impaired CMI early with some reconstitution after 6 weeks. All subjects showed some degree of malnutrition and/or depleted iron status.</p> |       |                                                |                                                                                      |                                              |                            |
| 20 DISTRIBUTION/AVAILABILITY OF ABSTRACT<br><input checked="" type="checkbox"/> UNCLASSIFIED/DUNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |       |                                                | 21 ABSTRACT SECURITY CLASSIFICATION<br>Unclassified                                  |                                              |                            |
| 22a NAME OF RESPONSIBLE INDIVIDUAL<br>RAM I: CAPT J.N. Woody                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |       |                                                | 22b TELEPHONE (Include Area Code)<br>(301) 663-7193                                  |                                              | 22c OFFICE SYMBOL<br>NMRDC |

DD Form 1473, JUN 86

Previous editions are obsolete

S/N 0102-LF-014-6603

SECURITY CLASSIFICATION OF THIS PAGE

UNCLASSIFIED